teroxirone has been researched along with Thrombophlebitis* in 3 studies
3 other study(ies) available for teroxirone and Thrombophlebitis
Article | Year |
---|---|
Phase I study of two schedules of teroxirone.
Two schedules of teroxirone, a triazine triepoxide, were evaluated in a phase I study. Twenty-six patients were treated on 1 day every 5 weeks at doses of 36-2250 mg/m2. At doses greater than or equal to 1500 mg/m2, severe thrombophlebitis was seen without cytotoxic effect, and this schedule was closed. Twenty-seven patients were treated on 5 days every 5 weeks at daily doses of 16-450 mg/m2. Mild thrombophlebitis and moderate leukopenia were encountered. For phase II studies, a dose of 375 mg/m2 X 5 every 5 weeks is recommended. Pharmacologic studies showed rapid plasma elimination, which suggests the agent's possible usefulness for regional infusion. Topics: Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Humans; Leukopenia; Neoplasms; Thrombophlebitis; Triazines | 1987 |
Phase I trial of teroxirone.
Teroxirone is a novel triepoxide, synthesized as an alkylator and showing a broad spectrum of preclinical activity. It has good cytotoxic activity against sublines of P388 and L1210 leukemias resistant to another alkylating agent, cyclophosphamide. Thirty-six patients received teroxirone as a single iv push for 5 sequential days every 4 weeks. The dose-limiting toxic effects were phlebitis and cutaneous "flare" reactions, with a maximal tolerated dose of 340 mg/m2/day X 5. Nausea, vomiting, and myelosuppression were present but were not dose-limiting at the maximal tolerated dose. This dose would probably be a reasonable dose for phase II trials, but could not be delivered repeatedly without a central line. Since the local reactions were very severe and unique, we believe that studies on the safety of repeated administration via a central line should be completed in animals before trials of systemic therapy in humans begin. Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hematologic Diseases; Humans; Infusions, Parenteral; Kinetics; Male; Middle Aged; Neoplasms; Thrombophlebitis; Triazines | 1984 |
Phase I clinical trial with alpha 1,3,5- triglycidyl-s-triazinetrione (NSC-296934).
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Infusions, Parenteral; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Thrombophlebitis; Triazines; Vomiting | 1981 |